Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APPLE study of paricalcitol in renal transplant recipients with persistent secondary hyperparathyroidism
2008-006380-36Phase 2Completed
- Sponsor
- Mario Negri Institute for Pharmacological Research
- Start
- Nov 2008
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of paricalcitol in secondary hyperparathyroidism (SHPT) (2 arms), sponsored by Mario Negri Institute for Pharmacological Research. Primary endpoints: Reduction in parathyroid hormone during paricalcitol treatment and Achievement of target parathyroid hormone range. Started Nov 2008; status: completed.
02
Drugs
paricalcitol
03
Conditions
secondary hyperparathyroidism (SHPT)
Beyond the preview
Go deeper on 2008-006380-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-006380-36.